Total Payments
$26,651
2024 Payments
$2,927
Companies
51
Transactions
715
Medicare Patients
2,785
Medicare Billing
$468,416
Payment Breakdown by Category
Food & Beverage$12,315 (46.2%)
Research$7,977 (29.9%)
Other$6,000 (22.5%)
Education$270.43 (1.0%)
Travel$87.71 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $12,315 | 688 | 46.2% |
| Unspecified | $7,977 | 9 | 29.9% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $6,000 | 3 | 22.5% |
| Education | $270.43 | 11 | 1.0% |
| Travel and Lodging | $87.71 | 4 | 0.3% |
Payments by Type
General
$18,673
706 transactions
Research
$7,977
9 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $7,977 | 9 | $0 (2021) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $5,333 | 72 | $0 (2024) |
| ABBVIE INC. | $3,427 | 231 | $0 (2024) |
| Valeant Pharmaceuticals North America LLC | $2,203 | 8 | $0 (2017) |
| Janssen Biotech, Inc. | $1,240 | 56 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $996.17 | 76 | $0 (2024) |
| Celgene Corporation | $661.90 | 54 | $0 (2024) |
| Boston Scientific Corporation | $601.35 | 7 | $0 (2024) |
| PFIZER INC. | $509.30 | 30 | $0 (2024) |
| QOL Medical, LLC | $374.14 | 26 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,927 | 131 | Janssen Biotech, Inc. ($527.21) |
| 2023 | $1,918 | 103 | AbbVie Inc. ($399.77) |
| 2022 | $2,125 | 120 | ABBVIE INC. ($697.59) |
| 2021 | $6,136 | 43 | Eli Lilly and Company ($5,417) |
| 2020 | $744.40 | 28 | Eli Lilly and Company ($422.31) |
| 2019 | $3,784 | 126 | Eli Lilly and Company ($2,138) |
| 2018 | $5,901 | 99 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($4,485) |
| 2017 | $3,116 | 65 | Valeant Pharmaceuticals North America LLC ($2,203) |
All Payment Transactions
715 individual payment records from CMS Open Payments — Page 1 of 29
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $20.96 | General |
| Category: Gastroenterology | ||||||
| 12/19/2024 | ERBE USA INC | vio 3 (Device) | Food and Beverage | Cash or cash equivalent | $50.00 | General |
| Category: Gastroenterology | ||||||
| 12/18/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $19.57 | General |
| Category: Immunology | ||||||
| 12/17/2024 | VIVUS LLC | QSYMIA (Drug) | Food and Beverage | In-kind items and services | $18.67 | General |
| Category: ENDOCRINOLOGY | ||||||
| 12/11/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $17.49 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/11/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug), XIFAXAN | Food and Beverage | In-kind items and services | $14.65 | General |
| Category: Gastroenterology | ||||||
| 12/09/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $25.74 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/09/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $16.56 | General |
| Category: LIVER DISEASE | ||||||
| 12/06/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $13.77 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/04/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $25.71 | General |
| Category: Immunology | ||||||
| 12/02/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $23.36 | General |
| Category: IMMUNOLOGY | ||||||
| 11/25/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $27.51 | General |
| 11/22/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $23.20 | General |
| Category: Immunology | ||||||
| 11/20/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $33.54 | General |
| Category: INTERNAL MEDICINE | ||||||
| 11/19/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $26.17 | General |
| Category: Immunology | ||||||
| 11/19/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $18.94 | General |
| Category: IMMUNOLOGY | ||||||
| 11/19/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $1.89 | General |
| Category: IMMUNOLOGY | ||||||
| 11/18/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug), XIFAXAN | Food and Beverage | In-kind items and services | $28.54 | General |
| Category: Gastroenterology | ||||||
| 11/13/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $16.00 | General |
| Category: Immunology | ||||||
| 11/11/2024 | ABBVIE INC. | VIBERZI (Drug), CREON | Food and Beverage | In-kind items and services | $9.58 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/07/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $24.48 | General |
| Category: IMMUNOLOGY | ||||||
| 11/04/2024 | ABBVIE INC. | CREON (Drug), LINZESS | Food and Beverage | In-kind items and services | $22.04 | General |
| Category: ENDOCRINOLOGY | ||||||
| 10/30/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $20.19 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/29/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $28.11 | General |
| Category: Immunology | ||||||
| 10/28/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $26.21 | General |
| Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED MAINTENANCE STUDY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 2) | Eli Lilly and Company | $4,915 | 3 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED INDUCTION STUDY OF MIRIKIZUMAB IN CONVENTIONAL-FAILED AND BIOLOGIC-FAILED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 1) | Eli Lilly and Company | $1,393 | 2 |
| AN ADAPTIVE PHASE 2, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LY3471851 (NKTR 358) IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | Eli Lilly and Company | $1,096 | 1 |
| A PHASE 3, MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS LUCENT 3 | Eli Lilly and Company | $317.56 | 2 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE- CONTROLLED, TREAT-THROUGH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE | Eli Lilly and Company | $255.82 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 667 | 719 | $532,922 | $82,899 |
| 2022 | 14 | 722 | 7,078 | $833,468 | $196,929 |
| 2021 | 16 | 747 | 822 | $384,691 | $110,780 |
| 2020 | 12 | 649 | 718 | $222,513 | $77,807 |
Total Patients
2,785
Total Services
9,337
Medicare Billing
$468,416
Procedure Codes
54
All Medicare Procedures & Services
54 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 106 | 106 | $151,156 | $24,021 | 15.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 88 | 101 | $35,148 | $10,747 | 30.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 75 | 97 | $33,368 | $9,880 | 29.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 92 | 103 | $24,411 | $7,261 | 29.7% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 68 | 71 | $83,850 | $6,070 | 7.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 46 | 46 | $24,932 | $5,843 | 23.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 37 | 38 | $25,460 | $5,736 | 22.5% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 23 | 23 | $25,246 | $4,539 | 18.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 39 | 39 | $13,962 | $3,062 | 21.9% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 62 | 62 | $93,000 | $2,543 | 2.7% |
| 43251 | Removal of polyps or growths of esophagus, stomach, and/or upper small bowel using an endoscope with mechanical snare | Facility | 2023 | 12 | 12 | $17,412 | $1,819 | 10.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 19 | 21 | $4,977 | $1,378 | 27.7% |
| J3380 | Injection, vedolizumab, 1 mg | Office | 2022 | 11 | 6,300 | $327,600 | $109,129 | 33.3% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 92 | 92 | $131,192 | $21,117 | 16.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 111 | 129 | $44,892 | $13,686 | 30.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 99 | 112 | $26,544 | $8,589 | 32.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 48 | 49 | $32,170 | $8,420 | 26.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 54 | 54 | $29,268 | $7,580 | 25.9% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 67 | 70 | $78,680 | $6,576 | 8.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 55 | 73 | $25,112 | $6,541 | 26.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 52 | 52 | $18,616 | $4,225 | 22.7% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 17 | 17 | $17,986 | $3,600 | 20.0% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 64 | 64 | $85,952 | $3,599 | 4.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 22 | 26 | $6,162 | $1,609 | 26.1% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 13 | 23 | $5,129 | $1,556 | 30.3% |
About Dr. Emil Valle, M.D
Dr. Emil Valle, M.D is a Gastroenterology healthcare provider based in Reston, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/21/2006. The National Provider Identifier (NPI) number assigned to this provider is 1497711238.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Emil Valle, M.D has received a total of $26,651 in payments from pharmaceutical and medical device companies, with $2,927 received in 2024. These payments were reported across 715 transactions from 51 companies. The most common payment nature is "Food and Beverage" ($12,315).
As a Medicare-enrolled provider, Valle has provided services to 2,785 Medicare beneficiaries, totaling 9,337 services with total Medicare billing of $468,416. Data is available for 4 years (2020–2023), covering 54 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Reston, VA
- Active Since 04/21/2006
- Last Updated 03/18/2008
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1497711238
Products in Payments
- XIFAXAN (Drug) $7,177
- Humira (Biological) $1,150
- ZEPOSIA (Drug) $891.06
- STELARA (Biological) $856.14
- RINVOQ (Biological) $689.94
- ENTYVIO (Biological) $483.22
- XELJANZ (Drug) $467.07
- SKYRIZI (Biological) $416.47
- DUPIXENT (Biological) $351.22
- HUMIRA (Biological) $310.82
- CREON (Drug) $296.27
- TREMFYA (Drug) $275.51
- Sucraid (Drug) $274.21
- LINZESS (Drug) $256.46
- Entyvio (Biological) $253.29
- EXALT Model D (Device) $204.18
- TRULANCE (Drug) $170.16
- ENDOFLIP (Device) $163.06
- VIBERZI (Drug) $147.23
- Trulance (Drug) $145.55
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Reston
Eduardo Noguera, M.d, M.D
Gastroenterology — Payments: $11,673
Gastroenterology $11,673
Alan Plotner, M.d, M.D
Gastroenterology — Payments: $11,076
Gastroenterology $11,076
Anita Wolke, M.d, M.D
Gastroenterology — Payments: $9,571
Gastroenterology $9,571
Andrew Axelrad, M.d, M.D
Gastroenterology — Payments: $8,438
Gastroenterology $8,438
Minal Patel, Md, MD
Gastroenterology — Payments: $6,990
Gastroenterology $6,990